Healthcare
United Therapeutics Corporation(UTHR)
Live Price
Offline$551.47
+0.58% today
1Y Change
+89.67%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $25.00B
- Revenue Growth
- +10.6%
- EPS Growth
- +14.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
United Therapeutics Corporation (UTHR) is a Healthcare stock with a market cap of $25.00B and listed on NASDAQ. The stock last traded around $551.47 and up 89.7% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +10.6%, EPS growth of +14.0%, a dividend yield of 0.0%. What stands out right now is revenue +10.6%, EPS +14.0%, free cash flow -3.7% with operating margin 46.9% and ROIC 15.9%. Valuation sits in the middle of the pack at P/E 18.9 and price/sales 7.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines UTHR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.6% vs +7.6% peer median
Operating Margin
Above sector median
+46.9% vs +19.4% peer median
P/E
Below sector median
18.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.6% and EPS at +14.0%, with operating margin around 46.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +0.0% | +4.5% | -1.6% |
2026 Feb 25, 2026 | +8.0% | -5.9% | -8.4% | +1.2% |
2025 Oct 29, 2025 | +3.9% | -0.4% | -1.7% | +7.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UTHR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
UTHR Max Drawdown
-10.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UTHR and SPY.
Company Overview
United Therapeutics Corporation
NASDAQ Global Select
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
- Leadership
- Martine A. Rothblatt
- IPO Date
- Jun 17, 1999
- Employees
- 1.3k
- Street Address
- 1040 Spring Street
- Mailing
- Silver Spring, MD, 20910
- Region
- Silver Spring, MD, US
- Reporting Currency
- USD
- Investor Line
- 301 608 9292
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.9
- EV/EBITDA
- 13.0
- Price/Sales
- 7.9
- Price/Book
- 3.6
Growth
- Revenue
- +10.6%
- EPS
- +14.0%
- Free Cash Flow
- -3.7%
Profitability
- Gross Margin
- 87.9%
- Operating Margin
- 46.9%
- Net Margin
- 41.9%
- ROE
- 19.3%
- ROIC
- 15.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 6.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.